Rare diseases
Investigational molecules
Locations
37 boulevard Gambetta, 76000 Rouen, France
CHU de Rouen - Hôpital Charles Nicolle in Rouen, France specialises in clinical trials of conditions such as Colon cancer, Critical illness, Factor VIII deficiency, Gastric cancer, and other specialisations. This site conducts important research.
The medical center is at the forefront of oncology research, with a particular focus on non-small cell lung cancer (NSCLC). The institution is dedicated to improving outcomes for patients with completely resected primary stage IB, II, and IIIA NSCLC through innovative therapeutic approaches.
By exploring the efficacy of adjuvant therapy with novel agents like MEDI4736, the center aims to enhance disease-free survival rates in patients with specific genetic profiles, such as those with PD-L1 expression and EGFR-ALK- status.
Clinical trials currently enrolling participants at this site.
Study of Epoetin Alfa for Critically Ill Patients with Traumatic Injury
FranceStudy of Oxaliplatin, Nivolumab, and Trifluridine/Tipiracil for Patients with Advanced Gastric, Esophageal, or Gastroesophageal Junction Cancer
FranceRandomized phase III adjuvant capecitabine plus temozolomide versus surveillance in patients with resected stage I‑III pancreatic neuroendocrine tumors
FranceStudy on Long-Term Effects of Efanesoctocog Alfa in Preventing Joint Bleeds in Patients with Hemophilia A
FranceStudy on Chemotherapy with Levoleucovorin, Capecitabine, and Folinic Acid for Patients Aged 70+ After Stage III Colon Cancer Surgery
FranceStudy on Hormonal Treatment with Leuprorelin Acetate for Prostate Cancer Patients at High Risk of Recurrence After Surgery
FranceStudy on Durvalumab for Patients with Completely Removed Non-Small Cell Lung Cancer
FranceGet verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.
See the offer for sitesTell us about your condition – we search every trial in Europe and connect you with the right site.
